G.L. Pharma

G.L. Pharma is an Austrian pharmaceutical company headquartered in Lannach, Styria, and operating under the Gerot Lannach brand. Its origins lie in Lannacher Heilmittel GmbH, established in Lannach in 1947. The business was acquired in 1966 by Leopold and Hannelore Bartenstein, establishing the ownership connection that later continued through the Bartenstein family and the Bahopharm group. The company’s present identity was shaped by the combination of Lannacher Heilmittel with Gerot Pharmazeutika, a pharmaceutical manufacturer based in Vienna. Gerot Pharmazeutika was acquired in 1997, and the two businesses were merged in 2009. The resulting company adopted the name G.L. Pharma, while continuing to use Gerot Lannach as its brand identity. G.L. Pharma GmbH is a subsidiary of Bahopharm GmbH; Genericon Pharma is identified as a sister company within the same group. G.L. Pharma manufactures medicines spanning a broad range of therapeutic areas rather than concentrating on a single disease category. The areas associated with the company include allergy treatment, antibacterial medicines, diabetes care, oncology, chronic pain and Parkinson’s disease. This breadth places the company within the diversified pharmaceutical-manufacturing segment, with a portfolio that includes both routine therapeutic products and medicines connected with public-health preparedness. One of the company’s most publicly documented products is potassium iodide in tablet form. These tablets are used for iodine thyroid blocking when radioactive iodine-131 may be released during a nuclear incident. In 2019, Germany’s Federal Office for Radiation Protection placed an order for 190 million iodine tablets, described as the largest single order in G.L. Pharma’s history. The order reflected the product’s role in emergency preparedness rather than ordinary consumer pharmaceutical demand. In spring 2019, G.L. Pharma began an expansion of its production facilities in Lannach. The investment was reported at €60 million and was intended to create capacity for approximately 100 additional jobs. The expansion illustrates the company’s role as a manufacturing and employment base in its home region, as well as its need to support production across a diverse portfolio. G.L. Pharma is headquartered at Lannach Castle and remains associated with the privately owned Bahopharm group. Publicly available reference material describes the company as an active Austrian pharmaceutical manufacturer, but does not provide enough information to establish a complete current executive roster, detailed product-by-product sales structure, or a definitive list of all markets in which its medicines are sold.

G.L. Pharma traces its history to Lannacher Heilmittel GmbH, which was founded in 1947 in Lannach, Styria. The company developed as an Austrian pharmaceutical enterprise serving a range of therapeutic needs. In 1966, it was acquired by Leopold and Hannelore Bartenstein. This transaction placed the business within the Bartenstein family’s ownership sphere, which later became associated with the Bahopharm group. A major structural change occurred in 1997, when the Vienna-based pharmaceutical manufacturer Gerot Pharmazeutika was purchased. The acquisition connected the Lannach operation with an established pharmaceutical business in Vienna and expanded the organizational base from which the later group could operate. In 2009, Lannacher Heilmittel and Gerot Pharmazeutika were merged. The combined business adopted the name G.L. Pharma and operated under the Gerot Lannach brand, a name reflecting the histories of the two constituent businesses. The merged company developed a broad pharmaceutical portfolio. Its therapeutic areas include medicines for allergies, bacterial infections, diabetes, cancer, chronic pain and Parkinson’s disease. In addition to conventional therapeutic products, the company manufactures potassium iodide tablets used in iodine thyroid blocking. These tablets are intended for situations in which radioactive iodine-131 could be released during a nuclear incident. Their purpose is to reduce the thyroid’s uptake of radioactive iodine and makes the product relevant to national emergency-preparedness programs. G.L. Pharma’s potassium iodide business gained particular public attention in 2019, when Germany’s Federal Office for Radiation Protection ordered 190 million tablets. The order was identified as the largest single order in the company’s history and represented a substantial public-sector procurement connected to nuclear emergency planning. Also in spring 2019, G.L. Pharma began expanding its Lannach production facilities. The investment was reported at €60 million and was intended to provide room for approximately 100 additional jobs. The project indicated continued investment in the company’s Austrian manufacturing base and supported its ability to produce medicines across its portfolio. The company is headquartered at Lannach Castle in Lannach, Styria. G.L. Pharma GmbH is described as a subsidiary of Bahopharm GmbH, which is owned by the Bartenstein family. Genericon Pharma is identified as a sister company within the Bahopharm group. Available reference material confirms the company’s active pharmaceutical-manufacturing role and its ownership structure, but does not establish a complete chronology of later product launches, a current executive list, or detailed revenue and geographic-market data.

• 2019

  Lannach manufacturing expansion begins

  [1]G.L. Pharmaen.wikipedia.org

  G.L. Pharma starts a reported €60 million expansion of its Lannach production facilities, planned to create space for approximately 100 new jobs.

• 2019

  Record potassium iodide order

  [1]G.L. Pharmaen.wikipedia.org

  Germany’s Federal Office for Radiation Protection orders 190 million iodine tablets for nuclear-emergency preparedness, described as G.L. Pharma’s largest single order.

• 2009

  Lannacher Heilmittel and Gerot Pharmazeutika merge

  [1]G.L. Pharmaen.wikipedia.org

  The two pharmaceutical businesses are merged to form G.L. Pharma, operating under the Gerot Lannach brand.

• 1997

  Gerot Pharmazeutika is purchased

  [1]G.L. Pharmaen.wikipedia.org

  The Vienna-based pharmaceutical manufacturer Gerot Pharmazeutika is acquired.

• 1966

  Bartenstein family acquires the predecessor company

  [1]G.L. Pharmaen.wikipedia.org

  Leopold and Hannelore Bartenstein acquire Lannacher Heilmittel, beginning the ownership relationship later associated with the Bartenstein family and Bahopharm.

• 1947

  Lannacher Heilmittel is founded

  [1]G.L. Pharmaen.wikipedia.org

  Lannacher Heilmittel GmbH, the predecessor of G.L. Pharma, is established in Lannach, Styria, Austria.

A diversified Austrian pharmaceutical manufacturer combining broad therapeutic coverage with specialized public-health and nuclear-emergency preparedness products.

• Emergency-preparedness medicine

  Potassium iodide tablets

  G.L. Pharma manufactures potassium iodide tablets used for iodine thyroid blocking in the event of a nuclear incident involving the release of radioactive iodine-131. The product is associated with public-sector emergency preparedness rather than routine treatment. In 2019, the company received a German government order for 190 million tablets, reported as the largest single order in its history.

• Allergy treatment

  Allergy medicines

  Allergy treatments form one of the therapeutic areas identified in G.L. Pharma’s pharmaceutical portfolio. The available reference material does not specify individual product names, formulations, active ingredients or launch dates, but places these medicines within the company’s broader multi-area manufacturing business.

• Anti-infective medicines

  Antibacterial medicines

  G.L. Pharma manufactures medicines for bacterial infections as part of its diversified therapeutic portfolio. Public reference material does not identify particular brands or molecules, so this entry represents the company’s documented therapeutic area rather than a single named product line.

• Diabetes care

  Diabetes medicines

  Diabetes treatment is among the disease areas served by G.L. Pharma. The company’s available encyclopedia reference describes the category but does not provide enough information to identify specific products, dosage forms, indications or market launches.

• Cancer treatment

  Oncology medicines

  G.L. Pharma’s portfolio includes medicines associated with cancer treatment. The available material does not enumerate the relevant products or therapies, but identifies oncology as one of the company’s principal therapeutic areas alongside allergy, infection, diabetes, pain and Parkinson’s disease treatments.

• Pain management

  Chronic-pain medicines

  Medicines for chronic pain are included among G.L. Pharma’s documented therapeutic offerings. No individual brand, active ingredient or launch date is specified in the available reference material, so the line is described at the therapeutic-area level.

• Neurology

  Parkinson’s disease medicines

  G.L. Pharma manufactures medicines for Parkinson’s disease, making neurology one of the therapeutic areas represented in its portfolio. The available source does not identify individual products or provide detailed information about their formulations, indications or launch history.

• 2019

  Expansion of Lannach production capacityStrategy

  Background

  G.L. Pharma sought to expand its production facilities at its Austrian base in Lannach.

  Action taken

  The company began a reported €60 million facilities investment designed to create space for approximately 100 new jobs.

  Aftermath

  The project reinforced Lannach as the company’s manufacturing and employment base, although the available source does not provide a final completion date or detailed capacity figures.

  Reported investment value. €60 million (2019)

  Source

• 2019

  Supply of potassium iodide tablets for German emergency preparednessOther

  Background

  Germany’s Federal Office for Radiation Protection required a large supply of iodine tablets as a precaution against a nuclear incident involving radioactive iodine-131.

  Action taken

  G.L. Pharma accepted an order for 190 million potassium iodide tablets.

  Aftermath

  The procurement became the largest single order in the company’s recorded history and highlighted its role in public-health preparedness.

  Source

• 2009

  Integration of the Lannach and Vienna pharmaceutical businessesM&A

  Background

  Following the 1997 purchase of Gerot Pharmazeutika, the businesses descended from Lannacher Heilmittel and Gerot Pharmazeutika were combined into a single organization.

  Action taken

  The two companies were merged to form G.L. Pharma, which operated under the Gerot Lannach brand.

  Aftermath

  The merger created the corporate structure associated with the present G.L. Pharma identity.

  Source

1. 1G.L. Pharmaen.wikipedia.org